For IPO Boutique's "scale of 1 to 5" BUY rating on Audeo Oncology, and our comprehensive analysis, click the "Buy Market Research" link.
About Audeo Oncology (adapted from Audeo Oncology prospectus): Audeo is a late stage biopharmaceutical company primarily focused on utilizing their Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. Audeo seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as "AURX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.